Effects of trimetazidine on ventricular remodeling in coronary artery disease patients with left ventricular hypertrophy: the rationale and design of a randomized controlled trial

BACKGROUND: Trimetazidine is a metabolic anti-ischemic agent, which increases the tolerance of cardiomyocytes to ischemia. However, few studies have explored the effect of trimetazidine on ventricular remodeling in coronary artery disease (CAD) patients undergoing percutaneous coronary intervention...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Lili, Luan, Yi, Li, Ya, Wang, Min, He, Jialin, Jin, Chongying, Zhang, Wenbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275498/
https://www.ncbi.nlm.nih.gov/pubmed/32503494
http://dx.doi.org/10.1186/s12872-020-01557-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275498/
https://www.ncbi.nlm.nih.gov/pubmed/32503494
http://dx.doi.org/10.1186/s12872-020-01557-3

Ejemplares similares